Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125458022 | 12545802 | 2 | F | 20160525 | 20160801 | 20160711 | 20160813 | EXP | FR-JNJFOC-20160706033 | JANSSEN | 77.62 | YR | E | M | Y | 0.00000 | 20160812 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125458022 | 12545802 | 1 | PS | XARELTO | RIVAROXABAN | 1 | Oral | Y | N | 202439 | 15 | MG | TABLET | QD | |||||
| 125458022 | 12545802 | 2 | SS | IDELALISIB | IDELALISIB | 1 | Oral | 42900 | MG | Y | 0 | 150 | MG | UNSPECIFIED | BID | ||||
| 125458022 | 12545802 | 3 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | Y | 0 | 375 | MG/M**2 | UNSPECIFIED | /month | ||||||
| 125458022 | 12545802 | 4 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | Y | 0 | 500 | MG/M**2 | UNSPECIFIED | /month | ||||||
| 125458022 | 12545802 | 5 | SS | ZELITREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 61000 | MG | Y | 0 | 500 | MG | UNSPECIFIED | QD | ||||
| 125458022 | 12545802 | 6 | SS | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 24400 | MG | Y | 0 | 200 | MG | UNSPECIFIED | QD | ||||
| 125458022 | 12545802 | 7 | SS | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | Oral | Y | 0 | 10 | MG | UNSPECIFIED | |||||||
| 125458022 | 12545802 | 8 | SS | FLECAINE | FLECAINIDE | 1 | Oral | 0 | 150 | MG | UNSPECIFIED | QD | |||||||
| 125458022 | 12545802 | 9 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Unknown | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125458022 | 12545802 | 1 | Transient ischaemic attack |
| 125458022 | 12545802 | 2 | Lymphoma |
| 125458022 | 12545802 | 3 | Lymphoma |
| 125458022 | 12545802 | 4 | Lymphoma |
| 125458022 | 12545802 | 5 | Prophylaxis |
| 125458022 | 12545802 | 6 | Lymphoma |
| 125458022 | 12545802 | 7 | Nausea |
| 125458022 | 12545802 | 8 | Transient ischaemic attack |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125458022 | 12545802 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125458022 | 12545802 | Dermatitis exfoliative |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125458022 | 12545802 | 1 | 20160104 | 0 | ||
| 125458022 | 12545802 | 2 | 20160104 | 20160525 | 0 | |
| 125458022 | 12545802 | 3 | 20160104 | 0 | ||
| 125458022 | 12545802 | 4 | 20160201 | 20160525 | 0 | |
| 125458022 | 12545802 | 5 | 201601 | 20160525 | 0 | |
| 125458022 | 12545802 | 6 | 201601 | 20160525 | 0 | |
| 125458022 | 12545802 | 7 | 201601 | 20160525 | 0 | |
| 125458022 | 12545802 | 8 | 20160104 | 0 | ||
| 125458022 | 12545802 | 9 | 20160104 | 20160120 | 0 |